Deversify AB has successfully completed a rights issue raising proceeds of SEK 11,2 million. The rights issue has primarily been subscribed for by new Swedish investors from all over the country. Net cash from the rights issue will be used for the continual building and strengthening of the organisation and to support the company’s commercial strategy.
”This rights issue is our largest by far and allows us to step into the next phase of business development and enterprise-building”, says Anders Murman, CEO. He continues: ”With our device, Acetrack, you can measure your rate of fat burning in real time. We are now focusing on accelerating the expansion of Acetrack in Europe and launching our updated, next generation, software. We will also be launching new projects on microsensors and new research on health data – everything to improve the understanding of individual metabolism”.